Chen Guo-Qiang, Luo Jian-bin, Wang Guang-Zhi, Ding Jin-E
Department of Urology, Second Hospital of Longyan City, Longyan, 364000, Fujian Province, China,
Tumour Biol. 2014 Mar;35(3):1875-9. doi: 10.1007/s13277-013-1250-9. Epub 2013 Dec 19.
Vascular endothelial growth factor (VEGF) plays a crucial role in the regulation of angiogenesis and is involved in the development and metastasis of common cancers. There were several case-controls studies published to assess the associations of VEGF polymorphisms with risk of prostate cancer, but the findings were inconsistent. We performed a meta-analysis to provide a comprehensive assessment of the associations of three VEGF polymorphisms with risk of prostate cancer. The pooled odds ratio (OR) with 95% confidence interval (95% CI) was calculated to assess the associations. Eleven individual case-control studies with a total of 5,209 cases of prostate cancer and 5,233 controls were finally included into our meta-analysis. Overall, VEGF rs833061 polymorphism was not associated with risk of prostate cancer (T versus C, OR = 1.14, 95% CI 0.91-1.44, P = 0.26; TT versus CC, OR = 1.09, 95% CI 0.67-1.76, P = 0.74; TT versus
CC/CT: OR = 1.46, 95% CI 0.67-3.18, P = 0.34; TT/CT versus CC, OR = 1.08, 95% CI 0.82-1.43, P = 0.59). VEGF rs3025039 polymorphism was also not associated with risk of prostate cancer (T versus C, OR = 1.03, 95% CI 0.91-1.16, P = 0.66; TT versus CC, OR = 1.82 95% CI 0.16-20.53, P = 0.63; TT versus CC/CT, OR = 2.00, 95% CI 0.18-22.41, P = 0.57; TT/CT versus CC, OR = 0.72, 95% CI 0.38-1.36, P = 0.31). VEGF rs2010963 polymorphism was not associated with risk of prostate cancer under three models (C versus G, OR = 1.17, 95% CI 0.92-1.48, P = 0.20; CC versus GG, OR = 2.28, 95% CI 0.90-5.75, P = 0.08; CC versus GG/GC, OR = 1.57, 95% CI 0.67-3.68, P = 0.30). In conclusison, current data suggest that those three VEGF polymorphisms are not obviously associated with risk of prostate cancer.
血管内皮生长因子（VEGF）在血管生成调节中起关键作用，并参与常见癌症的发生和转移。已有多项病例对照研究发表，以评估VEGF基因多态性与前列腺癌风险的关联，但研究结果并不一致。我们进行了一项荟萃分析，以全面评估三种VEGF基因多态性与前列腺癌风险的关联。计算合并比值比（OR）及95%置信区间（95%CI）以评估关联。最终，11项个体病例对照研究共5209例前列腺癌病例和5233例对照纳入我们的荟萃分析。总体而言，VEGF rs833061基因多态性与前列腺癌风险无关（T与C相比，OR = 1.14，95%CI 0.91 - 1.44，P = 0.26；TT与CC相比，OR = 1.09，95%CI 0.67 - 1.76，P = 0.74；TT与CC/CT相比：OR = 1.46，95%CI 0.67 - 3.18，P = 0.34；TT/CT与CC相比，OR = 1.08，95%CI 0.82 - 1.43，P = 0.59）。VEGF rs3025039基因多态性也与前列腺癌风险无关（T与C相比，OR = 1.03，95%CI 0.91 - 1.16，P = 0.66；TT与CC相比，OR = 1.82，95%CI 0.16 - 20.53，P = 0.63；TT与CC/CT相比，OR = 2.00，95%CI 0.18 - 22.41，P = 0.57；TT/CT与CC相比，OR = 0.72，95%CI 0.38 - 1.36，P = 0.31）。在三种模型下，VEGF rs2010963基因多态性与前列腺癌风险无关（C与G相比，OR = 1.17，95%CI 0.92 - 1.48，P = 0.20；CC与GG相比，OR = 2.28，95%CI 0.90 - 5.75，P = 0.08；CC与GG/GC相比，OR =
